CLEVELAND, May 31, 2011 /PRNewswire-USNewswire/ -- CardioInsight Technologies Inc., a leading developer of non-invasive electrocardiographic mapping technology used to improve the diagnosis and treatment guidance of electrical disorders of the heart, announced the appointment of Jim Bullock to its Board of Directors.
(Logo: http://photos.prnewswire.com/prnh/20110531/DC10432LOGO)
Mr. Bullock is a leader in the cardiac rhythm management field and most recently served as chief executive officer of Atritech, an electrophysiology company that was acquired by Boston Scientific earlier this year. Previously, Mr. Bullock served as the chief executive officer of Endocardial Solutions, a catheter-based cardiac mapping company that was acquired by St. Jude Medical in 2005.
"I'm excited to be joining CardioInsight's Board of Directors and am looking forward to working with their team to commercialize this innovative new product," said Mr. Bullock. "CardioInsight's non-invasive cardiac mapping system represents an important evolution in the field of cardiac mapping and addresses a number of significant clinical opportunities to improve the diagnosis and treatment guidance for cardiac arrhythmias and heart failure."
CardioInsight's ECVUE™ mapping technology, which non-invasively generates real time, 3-D images of the electrical activity of the heart by combining body surface electrical data with anatomical data obtained from imaging scans, is planned for commercial introduction in Europe later this year. A stateside launch is expected to follow in 2012.
"Jim's track record of commercializing innovative electrophysiology products speaks for itself," said Steve Arless, CardioInsight's chief executive officer. "His direct experience and insight into the cardiac mapping market will be an invaluable resource as we prepare to launch our mapping system later this year."
About CardioInsight Technologies Inc.
CardioInsight is commercializing a revolutionary technology called Electrocardiographic Mapping (ECM) that non-invasively generates 3D images of the electrical activity of the heart. The images help physicians more accurately treat certain heart ailments such as arrhythmias and congestive heart failure. ECM non-invasively generates real-time, whole heart images of the electrical activity on the surface of the heart by combining body surface electrical data with 3-D anatomical data obtained from imaging scans. The CardioInsight system reconstructs and displays 3D images and other useful measures of cardiac electrical activity as if the measurements were taken directly from the surface of the heart. The ability of ECM to generate accurate images of the heart's electrical activity and its potential to guide therapy in both cardiac arrhythmias and congestive heart failure has been demonstrated in over 300 patient studies sponsored by the Company.
SOURCE CardioInsight Technologies Inc.
Advertisement
(Logo: http://photos.prnewswire.com/prnh/20110531/DC10432LOGO)
Mr. Bullock is a leader in the cardiac rhythm management field and most recently served as chief executive officer of Atritech, an electrophysiology company that was acquired by Boston Scientific earlier this year. Previously, Mr. Bullock served as the chief executive officer of Endocardial Solutions, a catheter-based cardiac mapping company that was acquired by St. Jude Medical in 2005.
Advertisement
"I'm excited to be joining CardioInsight's Board of Directors and am looking forward to working with their team to commercialize this innovative new product," said Mr. Bullock. "CardioInsight's non-invasive cardiac mapping system represents an important evolution in the field of cardiac mapping and addresses a number of significant clinical opportunities to improve the diagnosis and treatment guidance for cardiac arrhythmias and heart failure."
CardioInsight's ECVUE™ mapping technology, which non-invasively generates real time, 3-D images of the electrical activity of the heart by combining body surface electrical data with anatomical data obtained from imaging scans, is planned for commercial introduction in Europe later this year. A stateside launch is expected to follow in 2012.
"Jim's track record of commercializing innovative electrophysiology products speaks for itself," said Steve Arless, CardioInsight's chief executive officer. "His direct experience and insight into the cardiac mapping market will be an invaluable resource as we prepare to launch our mapping system later this year."
About CardioInsight Technologies Inc.
CardioInsight is commercializing a revolutionary technology called Electrocardiographic Mapping (ECM) that non-invasively generates 3D images of the electrical activity of the heart. The images help physicians more accurately treat certain heart ailments such as arrhythmias and congestive heart failure. ECM non-invasively generates real-time, whole heart images of the electrical activity on the surface of the heart by combining body surface electrical data with 3-D anatomical data obtained from imaging scans. The CardioInsight system reconstructs and displays 3D images and other useful measures of cardiac electrical activity as if the measurements were taken directly from the surface of the heart. The ability of ECM to generate accurate images of the heart's electrical activity and its potential to guide therapy in both cardiac arrhythmias and congestive heart failure has been demonstrated in over 300 patient studies sponsored by the Company.
SOURCE CardioInsight Technologies Inc.
